Press Releases Archives - Page 4 of 103 - Lupin

BSE 2300.00 NSE 2307.90

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2300.00 NSE 2307.90

Lupin Launches Rivaroxaban for Oral Suspension in the United States

October 1, 2025

Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension

September 30, 2025

Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital

September 29, 2025

Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets

September 24, 2025

Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules

September 17, 2025

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi’s Long-Acting Injectable Platform

September 3, 2025

Lupin Launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity

August 20, 2025

Lupin Announces Licensing Deal for Ranibizumab Biosimilar

August 12, 2025

Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States

August 11, 2025

Lupin Q1 FY2026 Results

1 2 3 4 5 … 102 103

Search

Hit enter to search or ESC to close